Download a complete bibliography from each of our ongoing investigational programs below.
Tebipenem HBR
Lacasse E, Brouillette E, Larose A, et al. In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
Thomas J, Navre M, Rubio A, Coukell A. Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery. ACS Infect Dis. 2018 Nov 9;4(11):1536-1539.
Tebipenem HBR
Rubio A, Pucci MJ, Jain A. Characterization of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis. 2018 Oct 12;4(10):1436-1438.
Tebipenem HBR
SPR994 (oral carbapenem prodrug): what’s in the pipeline?
Tebipenem HBR
Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant versus susceptible urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
Current oral (PO) regimen options are suboptimal for hospitalized patients with urinary tract infections (UTI) due to contemporary resistant Enterobacteriaceae (ENT): a multicenter analysis
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multidrug resistant Enterobacteriaceae in a hollow fibre infection model
Tebipenem HBR
The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of SPR994 for multidrug resistant Enterobacteriaceae
Tebipenem HBR
Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522.
Tebipenem HBR
Antimicrobial activity of tebipenem (SPR859) against a global challenge set of Enterobacteriaceae isolates
Tebipenem HBR
In vitro activity of tebipenem (SPR859), tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae
Tebipenem HBR
Frequency of spontaneous mutations conferring reduced susceptibility to tebipenem (SPR859) among susceptible and extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae
Tebipenem HBR
Impact of varied test conditions on the in vitro activity of tebipenem (SPR859) and meropenem against urinary pathogens, including those expressing extended-spectrum beta-lactamases (ESBL)
Tebipenem HBR
In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative bacteria
Tebipenem HBR
Characterization of the mechanism of action of tebipenem (SPR859) in the Escherichia coli macromolecular synthesis assay
Tebipenem HBR
In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract model
Tebipenem HBR
In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM)
Tebipenem HBR
Antimicrobial activity assessment of tebipenem (SPR859) against an isolate collection causing urinary tract infections
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem for multi-drug resistant Enterobacteriaceae
Tebipenem HBR
Dose ranging and dose fractionation of tebipenem-pivoxil (SPR994) in neutropenic murine thigh models of gram-negative bacterial infection
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection
Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017 Jul 1;65(1):141-146.
SPR206
Zabawa TP, Pucci MJ, Parr TR Jr, Lister T. Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Curr Opin Microbiol. 2016 Oct;33:7-12.
Pucci MJ, Dougherty TJ. Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box. Curr Opin Microbiol. 2016 Oct;33:v-vii
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
